# Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients

> **NCT04817241** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 5 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration and Biopsy
- **DRUG:** Cytarabine
- **DRUG:** Daunorubicin
- **DRUG:** Decitabine and Cedazuridine
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT04817241
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-10
- **Primary completion:** 2025-06-06
- **Final completion:** 2026-11-05
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04817241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04817241, "Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04817241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*